Series B - Aro Biotherapeutics
Investment Firm
Overview
Aro Biotherapeutics develops tissue-targeted genetic medicines using Centyrins, a proprietary technology, to address complex diseases.
Announced Date
Nov 28, 2023
Funding Type
Series B
Highlights
Location
United States, North America
Social
Investor Lead
N/A
Participant Investors
1
| Investor Name |
|---|
 HealthCap |
Round Details and Background
Aro Biotherapeutics raised $41500000 on 2023-11-28 in Series B
Aro Biotherapeutics develops tissue-targeted genetic medicines using Centyrins, a proprietary technology, to address complex diseases.
Company Funding History
4
| Announcment Date | Transaction Name | Number Of Investors | Lead Investor | Money Raised |
|---|---|---|---|---|
| Dec 11, 2018 |  Venture Round - Aro Biotherapeutics | 2 | - | 13.0M |
| Jan 05, 2021 | Series A - Aro Biotherapeutics | 8 | - | 88.0M |
| Dec 12, 2022 | Series B - Aro Biotherapeutics | 1 | - | 24.0M |
| Nov 28, 2023 | Series B - Aro Biotherapeutics | 5 | - | 41.5M |
Recent Activity
There is no recent news or activity for this profile.